Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to pharmacy.

Rheumatology (L-Z)

Referral for Medication and Patient Management Program

₩OptiMed

Please fax a copy (fro	nt and back) of <u>all</u> the patient's	s pharma	icy and medic	al insura	nce cards	as well as a				nts	
	Patient Demographics						Provi	der Info	ormation		
Name	Sex 🗆 M 🗆 F				Prescriber						
	SSN				NPIDEA						
Phone	2 nd Phone				Practice Name						
Address	ddress Apt/Suite										
City, State, ZIP				City,	State, ZIP _						
Primary language, if other	r than English			_ Phon	e		Fax		Key contact		
This is a 🛛 🗆 New Rx	Trai	ning by	Prescriber's	office			Ship f	irst fill to	Prescriber's office	2	
🗆 Refill			Pharmacy to						Patient		
			□ Not needed		tion				Other		
Diagnosis			Clinical	Informa	ltion						
□ L40.50 Arthropathic ps	-						ate of ne	gative TB test			
L40.53 Psoriatic spond							FB test pending, will fax results				
🗆 L40.54 Psoriatic juvenil							•	sative or treated 🗆 Yes 🗆 No			
□ L40.59 Other psoriatic								🗆 lb 🗆 kg			
□ M06.9 Rheumatoid artl □ M08.00 Unspecified juv							-	🗆 in			
unspecified site	Concomitant medications Allergie						llergies _				
☐ M45.9 Ankylosing spon						therest	notes				
spine							_ 0	mer not	ະວ		
Other (include ICD-10)									0		
Medication									Quantity	Refills	
Olumiant [®] 2mg ^ (baricitinib)	□ Take one tablet (2 mg) PO o	nce daily.				Hgb (Date(s)			30 tablets		
^ <u>REQUIRED</u> : Notate or atta	ach a copy of patient's current CBC and O	CMP with LF	Ts. These labs an	d lipids sho	uld be assess	ed at baseline a	and rease	sessed at tl	ne recommended intervals		
Orencia [®] 125mg (abatacept)	□ Inject 125mg SQ once weekl	ly.							4 pens/syringes		
	blease locate the drug specific referral fo	orm at https	//www.optimodb	althoartoo	rs.com/rofor	rale					
					is.com/refer				28-day starter pack	Zero	
□ Otezla ® 30mg	■ Titration Starter Pack: Take as directed per package. •or- if 14-day starter pack already given to patient, check here □ Date provided							N/A	N/A		
(apremilast)	Maintenance: Take one tablet (30mg) PO twice daily.							□ 60 tablets			
			g) PO once daily		enal impaiı	ment).			□ 30 tablets		
□ Rinvoq [™] 15mg XR ^ (upadacitinib)	□ Take one tablet (15 mg) PO o Do not split, crush, or chew.		^ <u>REQUIRED</u>			Hgb Date(s)			30 tablets		
^REQUIRED: Notate or atta	ich a copy of patient's current CBC and C	CMP with LF	Ts These labs and	d linids sho	ild he assess	ed at baseline a	and rease	sessed at th	ne recommended intervals		
RECORED. Notate of alla			13. 111636 1003 011							•	
To order RITUXAN® / RITUXII	MAB IV infusion, please locate the RITU	XIMAB Infu	sion referral form	at <u>https://v</u>	www.optimed	lhealthpartners	.com/ref	errals			
□ Simponi[®] 50mg (golimumab)	□ Inject 50mg SQ once monthly. □ Other								1 pen/syringe □ Other		
	sion please locate the drug specific refe	vral form at	https://www.optiv	modboalthr	artnors com	/roforrals					
				neunearri	arthers.com						
□ Stelara®	Select dose: Recommender Recommender		0	with mor	lerate to se	were PsA· 90r	nσ				
(ustekinumab)	□ Initial: Inject 1 dose SQ on								□ 1 dose	Zero	
	5	n day 28, inject 1 dose SQ every 12 weeks						□ 1 dose			
Administration: OptiMed I	Infusion Center or Home Infusion Servic	es nurse to	administer Stelara	a SQ. Altern	atively, the p	atient may be tr	rained to	self-admir	ister as appropriate.		
□ Taltz [®] 80mg ^^	□ Initial: Inject 160mg (2 inject			tion) SO (Awooks			2 pens/syringes	Zero	
(ixekizumab)	Maintenance: Beginning w		0, ,	, ,	,		(four -	o Ontible "	1 pen/syringe		
) patients with coexistent moderate-to-		ue psoriasis, use ti	ne dosing re	• •		(Tound oi	n OptiMed'		torm).	
🗆 Xeljanz® 5mg ^	Take one tablet (5mg) PO tw *Dose adjustment: Take one	,		ailv		UIRED: Lymph	n		60 tablets30 tablets		
🗆 Xeljanz XR® 11mg ^		כ נטטופנ (טו	ng) i O ONCL U	any.	Hgb_	• •					
(tofacitinib)	🗆 Take one tablet (11mg) PO c	once daily.	Do not crush, s	plit, or ch	0 -			-	□ 30 tablets		
	severe renal impairment, moderate hep										
-	ach a copy of the patient's current CBC a										
Please note: To increase	adherence and patient accepta	ance all m	edications will	be dispe	nsed as pe	n-type inject	tors un	less unav	vallable or otherwise	specified.	
Provider Signature						Dat	e				
My signature for this prescript	tion confirms that the treatment(s) indic e prior authorization process and to pro					norize OptiMed	and its r			ine to initiate and	
•	, <u></u> p p						,		FV F SEE BEBRR		
V121919A											

<u>Confidentiality statement</u>: This message is intended only for the individual or institution to which it is addressed. This may contain information, which is confidential, privileged, and/or proprietary. This information may be exempt from disclosure under applicable laws including but not limited to HIPAA. If you are not the intended recipient, please note you are strictly prohibited from distributing, copying, or disseminating this information. If you received this information in error, please notify the sender noted above and destroy all transmitted material.